Attana receives contract research order from European Biotech company

Report this content

Attana has received an contract research order from an European Biotech company. The order is related to optimization of therapeutically antibodies. The order value is around 600 kSEK and is expected to be performed and delivered during Q3 and Q4 2018 and will affect the cash flow and financial result positively during these two quarters.  The contract is based on Attana’s patented cell-based biosensor and will included detailed interaction analysis between the antibodies and specific cells with the goal of selecting and improving the antibodies interaction characteristic in an biologically relevant environment.

Attana’s application specialists will perform experiments where the interactions between a specific target receptor in the cell membrane of the target cells and a number of different antibodies with therapeutic potential will be characterized with respect to interaction kinetics and binding affinity. The results will be used for selecting and optimizing the most suitable antibody molecules for further development.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
tel: + 46 8 674 57 00

This is information that Attana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at June 13 CET on 14.30 2018

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences.  To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit or contact





Documents & Links